CADL Stock Overview
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
+ 1 more risk
Candel Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.80|
|52 Week High||US$10.22|
|52 Week Low||US$1.47|
|1 Month Change||-5.26%|
|3 Month Change||-44.95%|
|1 Year Change||-81.96%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-74.29%|
Recent News & Updates
|CADL||US Biotechs||US Market|
Return vs Industry: CADL underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: CADL underperformed the US Market which returned -14.8% over the past year.
|CADL Average Weekly Movement||15.1%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CADL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CADL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.
Candel Therapeutics, Inc. Fundamentals Summary
|CADL fundamental statistics|
Is CADL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CADL income statement (TTM)|
|Cost of Revenue||US$4.49m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.42|
|Net Profit Margin||-9,692.00%|
How did CADL perform over the long term?See historical performance and comparison